Brought to you by 
ICN licenses exclusive worldwide rights to four Hoffman drugs
13 Jul 1999
Executive Summary
ICN Pharmaceuticals Inc. licensed exclusive worldwide rights, excluding India, to four Hoffman-La Roche drug products in exchange for $179mm-half of which will be paid in cash and half in stock at $31/share.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ICN licenses exclusive worldwide rights to four Hoffman drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice